Next Article in Journal
Evidence for Retrovirus and Paramyxovirus Infection of Multiple Bat Species in China
Previous Article in Journal
Potential for Introduction of Bat-Borne Zoonotic Viruses into the EU: A Review
Article Menu

Export Article

Viruses 2014, 6(5), 2122-2137; doi:10.3390/v6052122

Oncolytic Virotherapy of Canine and Feline Cancer
Department of Biochemistry, University of Wuerzburg, Wuerzburg D-97074, Germany
Genelux Corporation, San Diego Science Center, San Diego, CA 92109, USA
Department of Radiation Medicine and Applied Sciences, Rebecca and John Moores Comprehensive Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA
Authors to whom correspondence should be addressed.
Received: 5 March 2014; in revised form: 22 May 2014 / Accepted: 30 April 2014 / Published: 16 May 2014


: Cancer is the leading cause of disease-related death in companion animals such as dogs and cats. Despite recent progress in the diagnosis and treatment of advanced canine and feline cancer, overall patient treatment outcome has not been substantially improved. Virotherapy using oncolytic viruses is one promising new strategy for cancer therapy. Oncolytic viruses (OVs) preferentially infect and lyse cancer cells, without causing excessive damage to surrounding healthy tissue, and initiate tumor-specific immunity. The current review describes the use of different oncolytic viruses for cancer therapy and their application to canine and feline cancer.
cancer; canine and feline cancer therapy; oncolytic virus; oncolysis

1. Introduction

Cancer is among the top fatal diseases in domestic and feral dogs and cats [1,2,3,4,5]. Incidence of canine or feline cancer ranges from 1% to 2% and cancer currently accounts for about half of the deaths of domestic animals older than 10 years [1,6,7]. The most common forms of cancer in dogs and cats are skin, lymphoma, mammary, bone, connective tissue, and oral cancers [1,7]. The traditional and established methods for pet cancer treatment include surgery, radiation therapy, chemotherapy, hyperthermia and photodynamic therapy. However, the available treatment options for pet patients with advanced-stage disease are limited and the prognosis for such patients is very poor. Therefore, developing novel therapies, which may also work synergistically in combination with the conventional treatment options, is crucial.

One promising new therapeutic approach is oncolytic virotherapy. Oncolytic viruses (OVs) exhibit selective viral replication in tumors and metastases resulting in the killing of cancer cells and the initiation of tumor-specific immunity [8,9]. Several OVs including adenovirus, herpes simplex virus, vaccinia virus, Seneca Valley virus and reovirus are currently in human clinical trials, the most advanced of which is in Phase III [10,11]. In addition, in China, the oncolytic adenovirus H101 has been approved for combination therapy of human cancer patients [12].

In contrast to the progress of human oncolytic virotherapy, there are very few clinical trials using OVs for canine or feline cancer patients [13,14]. Since many forms of canine or feline neoplasms resemble their human counterparts in histological appearance, tumor genetics, biologic behavior, pathologic expression, recognized risk factors and response to therapy [15,16,17,18], it is reasonable to expect that the human clinical protocols will transfer directly to the treatment of pet cancer patients. There are strong similarities between naturally occurring human and canine cancers including colorectal carcinoma, fibrosarcoma, osteosarcoma, soft tissue sarcoma, Non-Hodgkin and Burkitt lymphomas and small lymphocytic lymphoma [19]. Several types of feline neoplasms such as squamous cell carcinoma and mammary carcinoma also show similarities in tumor biology, expression patterns and prognosis with human head and neck squamous cell carcinoma and a wide subset of human breast cancers [20,21]. As OVs show continuous promise in clinical application for treatment of many cancer types in human patients and considering the high similarity and increasing frequency of these cancers in pets, we believe that oncolytic virotherapy could soon be a reality also in veterinary medicine. Moreover the data from canine studies are more reliable and may be helpful in designing human clinical trials. The translation of oncolytic virotherapy from dogs to humans and the reverse could be a two-way street for development of drugs.

This review describes the most common classes of OVs and their progress in preclinical studies with canine and feline cancers. Presented are also the challenges and the major obstacles to the optimal practice of oncolytic virotherapy in pet cancer patients.

2. Oncolytic Virotherapy for Canine and Feline Cancers

Many wild type or recombinant viruses have been tested as oncolytic agents for treatment of canine or feline cancer. They include human and canine adenoviruses, canine distemper virus (CDV), reovirus and members of the poxvirus family such as vaccinia virus, recombinant canary poxvirus (ALVAC), NYVAC (derived from the Copenhagen vaccinia strain) and myxoma virus.

2.1. Adenoviruses

Adenoviruses have been widely characterized for oncolytic therapy in humans, but beyond this they have the ability to infect a broad range of cell types across many species [22,23]. For this reason, human and canine adenoviruses have been used as therapeutic agents for canine and feline cancers (Table 1). For example, human adenovirus 5 (Ad5) productively replicates in canine osteosarcoma, canine melanoma and canine mammary carcinoma cells [24,25]. Several Ad5-based adenoviral vectors expressing different genetic or molecular factors associated with cancer such as p53, CD40 ligand or feline IL-12 have been tested with success for treatment of different canine and feline tumors [26,27,28].

Table 1. Oncolytic viruses tested for canine and/or feline cancer therapy.
Table 1. Oncolytic viruses tested for canine and/or feline cancer therapy.
Virus strainVirus family/Virus typeStudy/Tumor type/Animal modelRef.
Canine adenovirus type 2 (CAV2)Adenoviridae (double stranded DNA viruses)Infection of canine osteosarcoma cells and osteosarcoma xenografted mice[29]
Human adenovirus type 5 (Ad5)AdenoviridaeInfection of canine osteosarcoma, melanoma and mammary carcinoma cells[24]
Ad5, CAV2AdenoviridaeInfection of canine cells and osteosarcoma xenografted mice[25]
CAV2AdenoviridaeInfection of canine osteosarcoma cells and healthy dogs[30]
CAV2AdenoviridaeTreatment of canine osteosarcoma xenografts using tumor cells as a carrier for CAV2[31]
Ad5-based vector with CD40 ligand (AdCD40L)AdenoviridaeTreatment of canine malignant melanoma patients[32,33]
Ad5-based vector encoding IL-12 (Ad hsp feline IL-12)AdenoviridaeTreatment of cats with soft tissue sarcoma[28]
Ad5-vector-mediated p53 gene transferAdenoviridaeTreatment of canine osteosarcoma xenografts[26]
Canine Distemper Virus (CDV)Paramyxoviridae (single stranded RNA viruses)Infection of canine lymphoid, osteosarcoma and melanoma cells [34]
ReovirusReoviridae (double stranded RNA viruses)Infection of canine mast cell tumor cells (MCT) and treatment of MCT xenograft mice[35]
Vaccinia virus (Lister) strain (GLV-1h68) Poxviridae (double stranded DNA viruses)Treatment of canine mammary adenoma and carcinoma and soft tissue sarcoma xenograft mice[36,37,38]
Vaccinia virus (Lister) strain expressing anti-VEGF antibody (GLV-1h109)PoxviridaeTreatment of canine soft tissue sarcoma and prostate xenograft mice[39]
Vaccinia virus (Lister) strain (LIVP 6.1.1)PoxviridaeTreatment of canine soft tissue sarcoma and prostate xenografted mice[40]
Vaccinia virus (Lister) strain expressing anti-VEGF antibody (GLV-5b451)PoxviridaeTreatment of feline mammary carcinoma xenograft mice[41]
Myxoma virus (MYXV)PoxviridaeInfection of different canine tumor cells[42]
Myxoma virus (MYXV)PoxviridaeInfection of feline carcinoma cells[43]
Canary pox virus expressing IL2 (ALVAC-fIL2) PoxviridaeTherapy of cats with feline fibrosarcomas [14]
Vaccinia virus (Copenhagen) strain expressing IL2 (NYVAC-fIL2)PoxviridaeTherapy of feline fibrosarcoma patients[14]

Abbreviations: Ad5—Human adenovirus type 5; CAV2—Canine adenovirus type 2; IL2—interleukin 2; IL-12—interleukin 12; fIL2—feline interleukin 2; VEGF—Vascular endothelial growth factor.

However, the level of human adenovirus replication in canine cells is about 2 logs lower than in human cells [24]. On the other hand, canine adenovirus, while not as well studied, displays significantly improved viral replication in canine cancer cells. The conditionally replicating canine adenovirus 2 (CAV2) with the osteocalcin promoter showed replication in canine osteosarcoma cells only [30] and a significant therapeutic effect in canine osteosarcoma xenografts [29,31]. In addition, administration of this modified canine adenovirus to normal dogs showed only moderate virus-associated toxicity [30]. However, clinical use of CAV2 and its vectors can, under some conditions, be limited by pre-existing vector immunity [44]. Therefore, strategies to overcome the pre-existing humoral and cellular adenovirus specific immunity in dogs should be developed (see Section 3.2).

The introduction and expression of heterologous genes by adenoviruses can lead to enhanced therapeutic activity. For example, the adenoviral vector, AdCD40L, expressing a CD40 ligand exhibited complete tumor regression in 5 of 19 canine melanoma patients after intratumoral injection [32]. The results suggest that AdCD40L therapy is safe as administered and could have beneficial effects in treatment of canine melanoma.

2.2. Morbilliviruses

Canine distemper virus (CDV) is an enveloped virus with a single stranded RNA genome belonging to the genus morbillivirus of the paramyxoviridae family. It is a close relative of measles virus (MV). In fact, both MV and CDV use a similar cellular receptor for entry into cells [45]. Historically, children with Hodgkin’s disease were observed to experience regression after concurrent MV infection [46]. These observations prompted the consideration of attenuated MV for the treatment of human lymphoma and, consequently, measles virus has shown promising anti-tumor activity against a variety of malignant neoplasms in both preclinical and clinical studies [47]. Because of its similarity to MV, CDV was considered for treatment of canine lymphoma. CDV binds to the cellular receptor, the signaling lymphocyte activation molecule (SLAM or CD150) [48], which is over-expressed on malignant canine B and T lymphocytes [34]. Attenuated CDV was able to infect canine lymphoma cells in cell culture via binding to CD150 and to induce apoptosis in these cells [34]. While preliminary, these results support the continued evaluation of CDV for the treatment of canine lymphoma.

Nevertheless, the most dogs are vaccinated against canine distemper virus and the high prevalence of virus-neutralizing antibodies is one major obstacle to the use of CDV in canine clinical trials. The use of vectors of non-canine origin like e.g., MV or removing key neutralizing epitopes on the surface of viral capsid proteins might help to avoid pre-existing immunity. In addition, intratumoral or mucosal virus application or administration of higher virus doses could also be a solution for pre-existing immunity problems (for general review see [49]).

2.3. Reovirus

Reovirus, a non-enveloped icosahedral virus with segmented double stranded RNA, has been extensively tested in oncolytic virotherapy of human cancers over the past decade. While its clinical development has advanced into phase II and III clinical trials with human cancer patients, it has been hardly studied as a canine or feline oncolytic agent. A very recent study demonstrated for the first time that canine mast cell tumors (MCT) were highly susceptible to reovirus infection in vitro [35]. In addition, a single intratumoral reovirus injection significantly regressed canine mast cell tumor xenografts [35]. However, reovirus also infected normal canine mast cells raising safety concerns. Subsequent studies should address these concerns before using reovirus as an oncolytic agent for canine cancer therapy.

2.4. Poxviruses

Several preclinical and clinical studies with vaccinia virus (VACV) strains have demonstrated promising oncolytic properties [50]. VACV is a double stranded DNA virus of the poxvirus family [51,52]. Since it was the first widely used vaccine (in over 200 million people), resulting in worldwide eradication of smallpox, much is known about its safety profile [53]. Three different oncolytic vaccinia virus strains, GL-ONC1/GLV-1h68, V-VET-1/LIVP 6.1.1 (Genelux Corporation, San Diego, CA, USA) and JX-594 (Jennerex Biotherapeutics, Inc., San Francisco, CA, USA) are now undergoing clinical trials with either human or canine cancer patients [40,54,55]. The JX-594 construct was derived from the Wyeth strain by deletion of the thymidine kinase (tk) gene via insertion of GM-CSF and lacZ genes [56]. LIVP 6.1.1 was isolated from a wild type stock of Lister strain of vaccinia virus (Lister strain, Institute of Viral Preparations (LIVP), Moscow, Russia) and represents a “native” virus (no genetic manipulations were conducted). Interestingly, the thymidine kinase (tk) gene of LIVP 6.1.1 virus is inactive [57]. Several groups have reported that TK-mutant vaccinia viruses are significantly attenuated and demonstrate enhanced tumor-specific replication in vivo [54,58]. GLV-1h68 (named GL-ONC1 as produced for clinical investigation) was developed from the Lister strain by inserting three expression cassettes encoding Renilla luciferase–Aequorea green fluorescent protein fusion (Ruc-GFP), LacZ, and β-glucuronidase into the F14.5L, J2R (thymidine kinase) and A56R (hemagglutinin) loci of the viral genome, respectively [54].

GLV-1h68 has been tested with success in the treatment of canine mammary adenoma, mammary carcinoma and soft tissue sarcoma in xenograft tumor models [36,37,38]. In all three models, significant inhibition of tumor growth was observed after a single systemic administration of GLV-1h68 [36,37,38]. Additionally, GLV-1h68 enabled the detection of metastases via optical imaging [59,60]. GLV-1h109, a variant of GLV-1h68, expressing the anti-VEGF (Vascular Endothelial Growth Factor) single chain antibody (scAb) GLAF-1, demonstrated strong antitumor effects in canine soft tissue sarcoma and prostate carcinoma xenograft models [39]. Localization of GLV-1h109 and expression of GLAF-1 in the tumor tissue inhibited tumor angiogenesis. Similar data was obtained by the use of the new recombinant oncolytic vaccinia virus strain GLV-5b451, a variant of LIVP 6.1.1, expressing GLAF-2, in a feline mammary carcinoma xenograft model [41]. GLAF-1 and GLAF-2 single chain antibodies are identical with exception that GLAF-1 contains a FLAG-tag for purification purposes [61].

The oncolytic effect of LIVP 6.1.1 was studied in a panel of four different canine cancer cell lines including soft tissue sarcoma STSA-1, melanoma CHAS, osteosarcoma D17 and prostate carcinoma DT08/40 cells [40]. LIVP 6.1.1 was shown to efficiently infect, replicate in and lyse all tested canine cancer cells in culture [40]. In addition, two subclones of LIVP, LIVP 6.1.1 and LIVP 1.1.1, have shown great promise in the treatment of STSA-1 and/or DT08/40 tumor xenografts [38,40]. Interestingly, DNA sequence analysis of LIVP 1.1.1 revealed that the thymidine kinase (tk) gene of this strain is also inactive [57].

A phase I clinical study is underway to evaluate the safety of intravenous administration of LIVP 6.1.1 for treatment of canine cancer patients at Angel Care Cancer Center, Carlsbad, CA, USA.

Oncolytic activity of several other poxviruses, such as ALVAC, NYVAC and myxoma virus, has been evaluated in canine and feline tumors. Despite the fact that myxoma virus (MYXV) replicates only in lagomorphs and is only pathogenic in the European rabbit, it has shown efficient infection in human cancer cell types. Constant activation of cellular transformation pathways and the inability of tumor cells to elicit antiviral immune response helps MYXV to replicate in human cancer cells [62,63]. Moreover, MYXV can infect and lyse various canine and feline tumor cells in vitro [42,43]. Further studies of myxoma virus as an oncolytic agent in vivo are needed to determine its potential in treating dog and cat cancers.

ALVAC-fIL2 and NYVAC-fIL2 are recombinant, non-replicating canary poxvirus and highly attenuated vaccinia virus, respectively, encoding the feline IL2 gene [14]. When combined with surgery and radiotherapy, treatment with either of these viruses prevented feline fibrosarcoma recurrence in cats [14].

2.5. What Could Be the Possible Mechanisms of Oncolytic Virus Mediated Tumor Ablation?

An oncolytic virus destroys tumors either by direct viral lysis of tumor cells [64,65], by destruction of the tumor vasculature [66], by induction of host antitumoral immune responses [67,68,69], or most likely, a combination of these mechanisms [11,70] (Figure 1). An increased infiltration of neutrophils, macrophages and natural killer (NK) cells to the tumor site might be involved in the VACV-mediated immune response in different canine cancer xenograft models [37,38,40]. The presence of such activated inflammatory cells in the tumor tissue may enhance the antitumoral effect by increasing the phagocytic or cytotoxic activities of these cells [71,72]. In addition, an increase in proinflammatory interferon-gamma (IFN-gamma), interleukin-2 (IL-2), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), interferon gamma-induced protein 10 (IP-10), macrophage inflammatory protein-1 alpha (MIP-1 alpha), macrophage inflammatory protein-1 beta (MIP-1 beta), monocyte chemotactic protein-1 (MCP-1), and monocyte chemotactic protein-3 (MCP-3) was observed in vaccinia virus infected canine xenografted mice [37,38]. Many of these proteins stimulate innate immunity mediated by dendritic cells, neutrophils, macrophages and NK cells.

OVs naturally prevent neoangiogenesis either by direct infection and destruction of tumor vasculature [66] or “vascular normalization” in tumor tissue, as described by Winker and colleagues [73]. Moreover, oncolytic viruses can be additionally armed to enhance their natural antiangiogenic ability. VEGF is a key regulator of tumor angiogenesis and several anti-VEGF strategies have been developed for the treatment of different cancers [74,75,76]. Vaccinia virus expressing anti-VEGF antibodies significantly decreased neoangiogenesis at the tumor site and inhibited tumor growth in canine and feline xenografts [39,41]. Thus, strategies employing virus-encoded and delivered anti-VEGF antibodies in combination with OV may be effective therapeutic approaches for pet cancer patients.

At the present there are not enough data from pet cancer patients treated with oncolytic viruses to allow an understanding of OV-mediated tumor ablation. However, it is expected that factors such as origin of tumor, stage of tumor development and combination therapy, and, importantly, the balance between antiviral and antitumoral immune responses will play a role.

Figure 1. Possible mechanisms of oncolytic virus mediated tumor ablation.
Figure 1. Possible mechanisms of oncolytic virus mediated tumor ablation.
Viruses 06 02122 g001 1024

Abbreviations: MФ: macrophages; NK: natural killer cells; DC: dendritic cells; Neutr.: neutrophils; IFN-gamma: interferon-gamma; IL-2: interleukin-2: IL-6: interleukin-6; TNF-alpha: tumor necrosis factor alpha: IP-10: interferon gamma-induced protein 10; MIP-1 alpha: macrophage inflammatory protein-1; MCP-1: monocyte chemotactic protein-1; MCP-3: monocyte chemotactic protein-3; TAA: tumor-associated antigens.

3. Open Questions Regarding the Use of Oncolytic Virotherapy in Veterinary Medicine

The major obstacles that restrict the optimal use of oncolytic viruses as therapeutics for canine or feline cancer patients are viral toxicity, ineffective delivery of virus to tumor and inefficient spread of OVs throughout the tumor mass.

3.1. Toxicity of Oncolytic Viruses to Pet Cancer Patients

As for all experimental therapeutic agents and treatments, a primary concern of virotherapy is toxicity. Treatment-related toxicity is common for chemotherapy and radiation therapy in canine or feline cancers [77,78,79]. While only a few clinical trials of oncolytic virotherapy in canine or feline cancer patients have been carried out, evidence for the lack of toxicity of OVs in pets is emerging. Intravenous administration of canine adenovirus-2 in normal dogs and AdCD40L (adenovector expressing the CD40 ligand) in canine malignant melanoma cases did not show any virus associated toxicity [30,80]. In a very recently completed phase I study, Westberg and colleagues reported that AdCD40L therapy in canine melanoma patients was safe and only mild adverse effects were associated with treatment [32]. Sufficient evidence of oncolytic viruses as a safe therapeutic modality is displayed by several studies [33,81,82]. Furthermore, genetic engineering of oncolytic viruses is supported by the safety data from genetically engineered products like DNA vaccine in dogs and non-human primates [83,84,85]. Overall both wild type and genetically engineered oncolytic virus therapy appears to be as safe as standard anti cancer therapies.

3.2. Optimization of OV Delivery to the Tumor Tissue and Metastases

Immune responses against therapeutic viruses may presumably hamper ongoing viral replication in immunocompetent dogs and cats. Several factors including neutralizing antibodies, inactivation by complement and sequestration in the liver and spleen could impair the effectiveness of the virus especially after intravenous virus application, the preferred route of administration for treatment of metastatic cancer. One of the most promising strategies to evade virus inactivation by these factors is carrier-based delivery. Several types of cells, such as immune cells [86], stem cells [87] and tumor cells [88] have been successfully utilized as carriers of OVs to the tumor.

Canine osteosarcoma cells treated with replication selective canine adenovirus (OCCAV) were used as virus carriers for evading pre-existing neutralizing antibodies against adenovirus. When administered systemically, even in the presence of adenovirus neutralizing antibodies, OCCAV carrier cells showed superior infection of tumors and tumor regression in a xenograft mouse model compared to OCCAV alone [31]. Moreover, the enhanced oncolytic effects were attributed to an increase in the effective local viral dose in the tumor as a consequence of the tumor-specific delivery of the virus by the cells and the escape of the pre-existing antiviral immunity [88,89].

In addition, virus coatings with biocompatible polymers such as polyethylene glycol (PEG) [90], silk-elastinlike protein [91] or N-[2-hydroxypropyl]meth-acrylamide (HPMA) [92] or with serum proteins [93,94] showed a minimized sequestration by the mononuclear phagocytic system in the liver and spleen. Furthermore, delivery of viruses within injectable polymer matrices has been shown to enhance antitumor effects compared to virus alone. Intratumoral injection of an adenovirus vector into human head and neck cancer xenograft tumors in a silk-elastinlike protein hydrogel increased the stability of the virus and the duration of its release into the tumor microenvironment [67].

In general, carrier-mediated deliveries of OVs may increase the efficiency of viral tumor colonization and protect the virus against the components of the host innate or acquired immune system.

3.3. Enhancing Viral Spread throughout the Tumor

The improvement of virus spread in tumor tissue is an important challenge for effective oncolytic virotherapy [95]. The tumor extracellular matrix (ECM) or stroma presents a substantial physical barrier to virus spread. Structural components of tumor ECM, such as collagens and proteoglycans, have been shown to hinder distribution of large therapeutic molecules and viruses [96]. Several groups have reported that the intratumoral spread and efficacy of OVs was improved by protease or hyaluronidase-mediated digestion of tumor ECM [97,98,99]. While preliminary, these results suggest that such strategies may be clinically useful.

3.4. Biosafety of Treatment

Oncolytic viruses also raise new biosafety and risk management issues [100,101]. The risk assessment for trials with these agents must take into account and mitigate the potential risk of transmission of the infectious agent to other pets and persons in contact with the treated patient. The zoonotic aspects or risk to pet owners and general public has to be monitored. The spectrum of diseases caused by parental viral strains in dogs or cats is an important safety factor for consideration. If necessary, the risk of disease or adverse effects from a viral therapeutic could be countered with antiviral agents effective against the viral strains considered for cancer treatment.

4. Conclusions

The significant incidence and mortality associated with canine and feline cancers continues to challenge modern veterinary medicine to develop more reliable therapies. One of the most promising novel cancer therapies is oncolytic virotherapy. This method is based on the capability of OVs to preferentially infect and lyse cancer cells and to initiate tumor-specific immunity. Several oncolytic viruses including human and canine adenoviruses, canine distemper virus (CDV), reovirus and vaccinia virus strains have been tested with convincing results in preclinical studies.

As for oncolytic virotherapy of human cancers, the most important challenges for the successful clinical use of OVs in veterinary practice are reduction of viral toxicity, optimization of virus delivery to tumor, and enhancement of viral spread throughout the tumor mass.

Recently, the first clinical studies with vaccinia and adenovirus for canine cancer therapy are underway and we look forward to the forthcoming demonstrations of clinical utility.


We would like to thank J. Stritzker, Q. Zhang, N. G. Chen, Y. A. Yu, A. MacNeill, I. Nolte, H. Murua Escobar and G. Ogilvie for providing data to the authors. N. G. Chen for critical reading of the manuscript. The original studies of I. Gentschev, I. Nolte, A. MacNeill and A. A. Szalay presented in this review were funded by Genelux Corporation, San Diego, CA, USA.

S. S. Patil is a graduate fellow and supported by a grant of the German Excellence Initiative to the Graduate School of Life Sciences, University of Wuerzburg.

Author Contributions

I.G., S.S.P., I.P., J.C., M.A. and A.A.S. participated in conceiving the review and writing the manuscript. All the authors read and approved the final manuscript.

Conflicts of Interest

I.G., J.C. and A.A.S. are employees and shareholders of Genelux Corporation, San Diego, CA, USA. M.A. and I.P. were supported by grants of Genelux Corporation awarded to University of Wuerzburg. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References and Notes

  1. Merlo, D.F.; Rossi, L.; Pellegrino, C.; Ceppi, M.; Cardellino, U.; Capurro, C.; Ratto, A.; Sambucco, P.L.; Sestito, V.; Tanara, G.; et al. Cancer incidence in pet dogs: Findings of the Animal Tumor Registry of Genoa, Italy. J. Vet. Intern. Med. 2008, 22, 976–984. [Google Scholar] [CrossRef]
  2. Dorn, E.R. Epidemiology of canine and feline tumors. J. Am. Anim. Hosp. Assoc. 1976, 12, 307–312. [Google Scholar]
  3. Gobar, G.M.; Case, J.T.; Kass, P.H. Program for surveillance of causes of death of dogs, using the Internet to survey small animal veterinarians. J. Am. Vet. Med. Assoc. 1998, 213, 251–256. [Google Scholar]
  4. Bronson, R.T. Variation in age at death of dogs of different sexes and breeds. Am. J. Vet. Res. 1982, 43, 2057–2059. [Google Scholar]
  5. Animal Health Survey In Companion Animal News, Englewood Colorado. Morris Animal Foundation. 1998 and 2005.
  6. Hansen, K.; Khanna, C. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. Eur. J. Cancer 2004, 40, 858–880. [Google Scholar] [CrossRef]
  7. Kelsey, J.L.; Moore, A.S.; Glickman, L.T. Epidemiologic studies of risk factors for cancer in pet dogs. Epidemiol. Rev. 1998, 20, 204–217. [Google Scholar] [CrossRef]
  8. Liu, T.C.; Galanis, E.; Kirn, D. Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 2007, 4, 101–117. [Google Scholar] [CrossRef]
  9. Chen, N.G.; Szalay, A.A. Oncolytic Virotherapy of Cancer. In Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures; Cancer Growth and Progression; Springer: New York, NY, USA, 2011; Volume 13, pp. 295–316. [Google Scholar]
  10. Bell, J.; McFadden, G. Viruses for Tumor Therapy. Cell Host Microbe 2014, 15, 260–265. [Google Scholar] [CrossRef]
  11. Russell, S.J.; Peng, K.W.; Bell, J.C. Oncolytic virotherapy. Nat. Biotechnol. 2012, 30, 658–670. [Google Scholar] [CrossRef]
  12. Garber, K. China approves world’s first oncolytic virus therapy for cancer treatment. J. Natl. Cancer Inst. 2006, 98, 298–300. [Google Scholar] [CrossRef]
  13. Patil, S.S.; Gentschev, I.; Nolte, I.; Ogilvie, G.; Szalay, A.A. Oncolytic virotherapy in veterinary medicine: Current status and future prospects for canine patients. J. Transl. Med. 2012, 10, 3. [Google Scholar] [CrossRef]
  14. Jourdier, T.M.; Moste, C.; Bonnet, M.C.; Delisle, F.; Tafani, J.P.; Devauchelle, P.; Tartaglia, J.; Moingeon, P. Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2). Gene Ther. 2003, 10, 2126–2132. [Google Scholar] [CrossRef]
  15. Paoloni, M.; Khanna, C. Translation of new cancer treatments from pet dogs to humans. Nat. Rev. Cancer 2008, 8, 147–156. [Google Scholar] [CrossRef]
  16. Khanna, C.; London, C.; Vail, D.; Mazcko, C.; Hirschfeld, S. Guiding the optimal translation of new cancer treatments from canine to human cancer patients. Clin. Cancer Res. 2009, 15, 5671–5677. [Google Scholar] [CrossRef]
  17. De Maria, R.; Olivero, M.; Iussich, S.; Nakaichi, M.; Murata, T.; Biolatti, B.; Di Renzo, M.F. Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Res. 2005, 65, 907–912. [Google Scholar]
  18. Tang, J.; Le, S.; Sun, L.; Yan, X.; Zhang, M.; Macleod, J.; Leroy, B.; Northrup, N.; Ellis, A.; Yeatman, T.J.; et al. Copy number abnormalities in sporadic canine colorectal cancers. Genome Res. 2010, 20, 341–350. [Google Scholar] [CrossRef]
  19. Rowell, J.L.; McCarthy, D.O.; Alvarez, C.E. Dog models of naturally occurring cancer. Trends Mol. Med. 2011, 17, 380–388. [Google Scholar] [CrossRef]
  20. Wypij, J.M. A naturally occurring feline model of head and neck squamous cell carcinoma. Pathol. Res. Int. 2013, 2013, 502197:1–502197:7. [Google Scholar] [CrossRef]
  21. Vail, D.M.; MacEwen, E.G. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer investigation 2000, 18, 781–792. [Google Scholar] [CrossRef]
  22. Nemunaitis, J.; Cunningham, C. Emerging new therapies for chemotherapy-resistant cancer using adenoviral vectors. Drug Resist. Updates 2002, 5, 34–46. [Google Scholar] [CrossRef]
  23. Yu, W.; Fang, H. Clinical trials with oncolytic adenovirus in China. Curr. Cancer Drug Targets 2007, 7, 141–148. [Google Scholar] [CrossRef]
  24. Ternovoi, V.V.; Le, L.P.; Belousova, N.; Smith, B.F.; Siegal, G.P.; Curiel, D.T. Productive replication of human adenovirus type 5 in canine cells. J. Virol. 2005, 79, 1308–1311. [Google Scholar] [CrossRef]
  25. Le, L.P.; Rivera, A.A.; Glasgow, J.N.; Ternovoi, V.V.; Wu, H.; Wang, M.; Smith, B.F.; Siegal, G.P.; Curiel, D.T. Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells. Gene Ther. 2006, 13, 389–399. [Google Scholar] [CrossRef]
  26. Kanaya, N.; Yazawa, M.; Goto-Koshino, Y.; Mochizuki, M.; Nishimura, R.; Ohno, K.; Sasaki, N.; Tsujimoto, H. Anti-tumor effect of adenoviral vector-mediated p53 gene transfer on the growth of canine osteosarcoma xenografts in nude mice. J. Vet. Med. Sci. 2011, 73, 877–883. [Google Scholar] [CrossRef]
  27. Thacker, E.E.; Nakayama, M.; Smith, B.F.; Bird, R.C.; Muminova, Z.; Strong, T.V.; Timares, L.; Korokhov, N.; O’Neill, A.M.; de Gruijl, T.D.; et al. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine 2009, 27, 7116–7124. [Google Scholar] [CrossRef]
  28. Siddiqui, F.; Li, C.Y.; Larue, S.M.; Poulson, J.M.; Avery, P.R.; Pruitt, A.F.; Zhang, X.; Ullrich, R.L.; Thrall, D.E.; Dewhirst, M.W.; et al. A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas. Mol. Cancer Ther. 2007, 6, 380–389. [Google Scholar] [CrossRef]
  29. Hemminki, A.; Kanerva, A.; Kremer, E.J.; Bauerschmitz, G.J.; Smith, B.F.; Liu, B.; Wang, M.; Desmond, R.A.; Keriel, A.; Barnett, B.; et al. A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol. Ther. 2003, 7, 163–173. [Google Scholar] [CrossRef]
  30. Smith, B.F.; Curiel, D.T.; Ternovoi, V.V.; Borovjagin, A.V.; Baker, H.J.; Cox, N.; Siegal, G.P. Administration of a conditionally replicative oncolytic canine adenovirus in normal dogs. Cancer Biother. Radiopharm. 2006, 21, 601–606. [Google Scholar] [CrossRef]
  31. Alcayaga-Miranda, F.; Cascallo, M.; Rojas, J.J.; Pastor, J.; Alemany, R. Osteosarcoma cells as carriers to allow antitumor activity of canine oncolytic adenovirus in the presence of neutralizing antibodies. Cancer Gene Ther. 2010, 17, 792–802. [Google Scholar] [CrossRef]
  32. Westberg, S.; Sadeghi, A.; Svensson, E.; Segall, T.; Dimopoulou, M.; Korsgren, O.; Hemminki, A.; Loskog, A.S.; Totterman, T.H.; von Euler, H. Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma. J. Immunother. 2013, 36, 350–358. [Google Scholar] [CrossRef]
  33. Von Euler, H.; Sadeghi, A.; Carlsson, B.; Rivera, P.; Loskog, A.; Segall, T.; Korsgren, O.; Totterman, T.H. Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma. J. Immunother. 2008, 31, 377–384. [Google Scholar] [CrossRef]
  34. Suter, S.E.; Chein, M.B.; von Messling, V.; Yip, B.; Cattaneo, R.; Vernau, W.; Madewell, B.R.; London, C.A. In vitro canine distemper virus infection of canine lymphoid cells: A prelude to oncolytic therapy for lymphoma. Clin. Cancer Res. 2005, 11, 1579–1587. [Google Scholar] [CrossRef]
  35. Hwang, C.C.; Umeki, S.; Kubo, M.; Hayashi, T.; Shimoda, H.; Mochizuki, M.; Maeda, K.; Baba, K.; Hiraoka, H.; Coffey, M.; et al. Oncolytic reovirus in canine mast cell tumor. PLoS One 2013, 8, e73555. [Google Scholar] [CrossRef]
  36. Gentschev, I.; Stritzker, J.; Hofmann, E.; Weibel, S.; Yu, Y.A.; Chen, N.; Zhang, Q.; Bullerdiek, J.; Nolte, I.; Szalay, A.A. Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: Preclinical development of a therapeutic agent. Cancer Gene Ther. 2009, 16, 320–328. [Google Scholar] [CrossRef]
  37. Gentschev, I.; Ehrig, K.; Donat, U.; Hess, M.; Rudolph, S.; Chen, N.; Yu, Y.A.; Zhang, Q.; Bullerdiek, J.; Nolte, I.; et al. Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68. J. Oncol. 2010, 2010, 736907:1–736907:10. [Google Scholar]
  38. Gentschev, I.; Adelfinger, M.; Josupeit, R.; Rudolph, S.; Ehrig, K.; Donat, U.; Weibel, S.; Chen, N.G.; Yu, Y.A.; Zhang, Q.; et al. Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma. PLoS One 2012, 7, e37239. [Google Scholar] [CrossRef]
  39. Patil, S.S.; Gentschev, I.; Adelfinger, M.; Donat, U.; Hess, M.; Weibel, S.; Nolte, I.; Frentzen, A.; Szalay, A.A. Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody. PLoS One 2012, 7, e47472. [Google Scholar] [CrossRef]
  40. Gentschev, I.; Patil, S.S.; Adelfinger, M.; Weibel, S.; Geissinger, U.; Frentzen, A.; Chen, N.G.; Yu, Y.A.; Zhang, Q.; Ogilvie, G.; et al. Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy. Bioengineered 2013, 4, 84–89. [Google Scholar] [CrossRef]
  41. Adelfinger, M.; Gentschev, I.; Grimm de Guibert, J.; Weibel, S.; Härtl, B.; Chen, N.G.; Yu, Y.A.; Zhang, Q.; Frentzen, A.; Szalay, A.A. Evaluation of a new recombinant oncolytic vaccinia virus strain GLV-5b451 for feline mammary carcinoma therapy. PLoS One 2014. submitted for publication. [Google Scholar]
  42. Urbasic, A.S.; Hynes, S.; Somrak, A.; Contakos, S.; Rahman, M.M.; Liu, J.; MacNeill, A.L. Oncolysis of canine tumor cells by myxoma virus lacking the serp2 gene. Am. J. Vet. Res. 2012, 73, 1252–1261. [Google Scholar] [CrossRef]
  43. MacNeill, A.L.; Moldenhauer, T.; Doty, R.; Mann, T. Myxoma virus induces apoptosis in cultured feline carcinoma cells. Res. Vet. Sci. 2012, 93, 1036–1038. [Google Scholar] [CrossRef]
  44. Bru, T.; Salinas, S.; Kremer, E.J. An update on canine adenovirus type 2 and its vectors. Viruses 2010, 2, 2134–2153. [Google Scholar] [CrossRef]
  45. Sato, H.; Yoneda, M.; Honda, T.; Kai, C. Morbillivirus receptors and tropism: Multiple pathways for infection. Front. Microbiol. 2012, 3, 75. [Google Scholar]
  46. Bluming, A.Z.; Ziegler, J.L. Regression of Burkitt’s lymphoma in association with measles infection. Lancet 1971, 2, 105–106. [Google Scholar] [CrossRef]
  47. Russell, S.J.; Peng, K.W. Measles virus for cancer therapy. Curr. Top. Microbiol. Immunol. 2009, 330, 213–241. [Google Scholar]
  48. Tatsuo, H.; Ono, N.; Tanaka, K.; Yanagi, Y. SLAM (CD150) is a cellular receptor for measles virus. Nature 2000, 406, 893–897. [Google Scholar] [CrossRef]
  49. Saxena, M.; Van, T.T.; Baird, F.J.; Coloe, P.J.; Smooker, P.M. Pre-existing immunity against vaccine vectors—Friend or foe? Microbiology 2013, 159, 1–11. [Google Scholar] [CrossRef]
  50. Chen, N.G.; Szalay, A.A. Oncolytic vaccinia virus: A theranostic agent for cancer. Future Virol. 2010, 5, 763–784. [Google Scholar] [CrossRef]
  51. Moss, B.; Earl, P.L. Overview of the vaccinia virus expression system. Curr. Protoc. Protein Sci. 2001. [CrossRef]
  52. Shchelkunov, S.N.; Totmenin, A.V.; Babkin, I.V.; Safronov, P.F.; Ryazankina, O.I.; Petrov, N.A.; Gutorov, V.V.; Uvarova, E.A.; Mikheev, M.V.; Sisler, J.R.; et al. Human monkeypox and smallpox viruses: Genomic comparison. FEBS Lett. 2001, 509, 66–70. [Google Scholar] [CrossRef]
  53. Fenner, F. The global eradication of smallpox. Med. J. Aust. 1980, 1, 455–456. [Google Scholar]
  54. Zhang, Q.; Yu, Y.A.; Wang, E.; Chen, N.; Danner, R.L.; Munson, P.J.; Marincola, F.M.; Szalay, A.A. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res. 2007, 67, 10038–10046. [Google Scholar] [CrossRef]
  55. Dranoff, G. GM-CSF-based cancer vaccines. Immunol. Rev. 2002, 188, 147–154. [Google Scholar] [CrossRef]
  56. Park, B.H.; Hwang, T.; Liu, T.C.; Sze, D.Y.; Kim, J.S.; Kwon, H.C.; Oh, S.Y.; Han, S.Y.; Yoon, J.H.; Hong, S.H.; et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: A phase I trial. Lancet Oncol. 2008, 9, 533–542. [Google Scholar] [CrossRef]
  57. Chen, N.G.; Zhang, Q.; Yu, Y.A.; Szalay, A.A. Vaccinia virus LIVP subclones: Comparative genomic features. 2014. to be submitted for publication. [Google Scholar]
  58. McCart, J.A.; Ward, J.M.; Lee, J.; Hu, Y.; Alexander, H.R.; Libutti, S.K.; Moss, B.; Bartlett, D.L. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001, 61, 8751–8757. [Google Scholar]
  59. Kelly, K.J.; Brader, P.; Woo, Y.; Li, S.; Chen, N.; Yu, Y.A.; Szalay, A.A.; Fong, Y. Real-time intraoperative detection of melanoma lymph node metastases using recombinant vaccinia virus GLV-1h68 in an immunocompetent animal model. Int. J. Cancer 2009, 124, 911–918. [Google Scholar] [CrossRef]
  60. Donat, U.; Weibel, S.; Hess, M.; Stritzker, J.; Hartl, B.; Sturm, J.B.; Chen, N.G.; Gentschev, I.; Szalay, A.A. Preferential colonization of metastases by oncolytic vaccinia virus strain GLV-1h68 in a human PC-3 prostate cancer model in nude mice. PLoS One 2012, 7, e45942. [Google Scholar] [CrossRef]
  61. Frentzen, A.; Yu, Y.A.; Chen, N.; Zhang, Q.; Weibel, S.; Raab, V.; Szalay, A.A. Anti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapy. Proc. Natl. Acad. Sci. USA 2009, 106, 12915–12920. [Google Scholar]
  62. Bartee, E.; Mohamed, M.R.; Lopez, M.C.; Baker, H.V.; McFadden, G. The addition of tumor necrosis factor plus beta interferon induces a novel synergistic antiviral state against poxviruses in primary human fibroblasts. J. Virol. 2009, 83, 498–511. [Google Scholar] [CrossRef]
  63. Wang, G.; Barrett, J.W.; Stanford, M.; Werden, S.J.; Johnston, J.B.; Gao, X.; Sun, M.; Cheng, J.Q.; McFadden, G. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc. Natl. Acad. Sci. USA 2006, 103, 4640–4645. [Google Scholar] [CrossRef]
  64. Chu, R.L.; Post, D.E.; Khuri, F.R.; van Meir, E.G. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin. Cancer Res. 2004, 10, 5299–5312. [Google Scholar] [CrossRef]
  65. Weibel, S.; Raab, V.; Yu, Y.A.; Worschech, A.; Wang, E.; Marincola, F.M.; Szalay, A.A. Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection. BMC Cancer 2011, 11, 68. [Google Scholar] [CrossRef]
  66. Breitbach, C.J.; Paterson, J.M.; Lemay, C.G.; Falls, T.J.; McGuire, A.; Parato, K.A.; Stojdl, D.F.; Daneshmand, M.; Speth, K.; Kirn, D.; et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol. Ther. 2007, 15, 1686–1693. [Google Scholar] [CrossRef]
  67. Prestwich, R.J.; Errington, F.; Diaz, R.M.; Pandha, H.S.; Harrington, K.J.; Melcher, A.A.; Vile, R.G. The case of oncolytic viruses versus the immune system: Waiting on the judgment of Solomon. Hum. Gene Ther. 2009, 20, 1119–1132. [Google Scholar] [CrossRef]
  68. Prestwich, R.J.; Harrington, K.J.; Pandha, H.S.; Vile, R.G.; Melcher, A.A.; Errington, F. Oncolytic viruses: A novel form of immunotherapy. Expert Rev. Anticancer Ther. 2008, 8, 1581–1588. [Google Scholar] [CrossRef]
  69. Toda, M.; Rabkin, S.D.; Kojima, H.; Martuza, R.L. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum. Gene Ther. 1999, 10, 385–393. [Google Scholar] [CrossRef]
  70. Atherton, M.J.; Lichty, B.D. Evolution of oncolytic viruses: Novel strategies for cancer treatment. Immunotherapy 2013, 5, 1191–1206. [Google Scholar] [CrossRef]
  71. Fridlender, Z.G.; Sun, J.; Kim, S.; Kapoor, V.; Cheng, G.; Ling, L.; Worthen, G.S.; Albelda, S.M. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell 2009, 16, 183–194. [Google Scholar]
  72. Moehler, M.H.; Zeidler, M.; Wilsberg, V.; Cornelis, J.J.; Woelfel, T.; Rommelaere, J.; Galle, P.R.; Heike, M. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum. Gene Ther. 2005, 16, 996–1005. [Google Scholar] [CrossRef]
  73. Winkler, F.; Kozin, S.V.; Tong, R.T.; Chae, S.S.; Booth, M.F.; Garkavtsev, I.; Xu, L.; Hicklin, D.J.; Fukumura, D.; di Tomaso, E.; et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6, 553–563. [Google Scholar]
  74. Ferrara, N.; Gerber, H.P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 2003, 9, 669–676. [Google Scholar] [CrossRef]
  75. Kamstock, D.; Elmslie, R.; Thamm, D.; Dow, S. Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol. Immunother. 2007, 56, 1299–1309. [Google Scholar] [CrossRef]
  76. Millanta, F.; Lazzeri, G.; Vannozzi, I.; Viacava, P.; Poli, A. Correlation of vascular endothelial growth factor expression to overall survival in feline invasive mammary carcinomas. Vet. Pathol. 2002, 39, 690–696. [Google Scholar] [CrossRef]
  77. Heading, K.L.; Brockley, L.K.; Bennett, P.F. CCNU (lomustine) toxicity in dogs: A retrospective study (2002–07). Aust. Vet. J. 2011, 89, 109–116. [Google Scholar]
  78. Price, G.S.; Page, R.L.; Fischer, B.M.; Levine, J.F.; Gerig, T.M. Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma. J. Vet. Intern. Med. 1991, 5, 259–262. [Google Scholar]
  79. Vail, D.M. Supporting the veterinary cancer patient on chemotherapy: Neutropenia and gastrointestinal toxicity. Top. Companion Anim. Med. 2009, 24, 122–129. [Google Scholar]
  80. Von Euler, H.P.; Rivera, P.; Aronsson, A.C.; Bengtsson, C.; Hansson, L.O.; Eriksson, S.K. Monitoring therapy in canine malignant lymphoma and leukemia with serum thymidine kinase 1 activity—Evaluation of a new, fully automated non-radiometric assay. Int. J. Oncol. 2009, 34, 505–510. [Google Scholar]
  81. Barton, K.N.; Paielli, D.; Zhang, Y.; Koul, S.; Brown, S.L.; Lu, M.; Seely, J.; Kim, J.H.; Freytag, S.O. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol. Ther. 2006, 13, 347–356. [Google Scholar]
  82. Freytag, S.O.; Barton, K.N.; Brown, S.L.; Narra, V.; Zhang, Y.; Tyson, D.; Nall, C.; Lu, M.; Ajlouni, M.; Movsas, B.; et al. Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. Mol. Ther. 2007, 15, 1600–1606. [Google Scholar]
  83. Su, C.; Cao, H.; Tan, S.; Huang, Y.; Jia, X.; Jiang, L.; Wang, K.; Chen, Y.; Long, J.; Liu, X.; et al. Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates. Toxicol. Sci. 2008, 106, 242–250. [Google Scholar]
  84. Peruzzi, D.; Gavazza, A.; Mesiti, G.; Lubas, G.; Scarselli, E.; Conforti, A.; Bendtsen, C.; Ciliberto, G.; La Monica, N.; Aurisicchio, L. A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma. Mol. Ther. 2010, 18, 1559–1567. [Google Scholar]
  85. Pluhar, G.E.; Grogan, P.T.; Seiler, C.; Goulart, M.; Santacruz, K.S.; Carlson, C.; Chen, W.; Olin, M.R.; Lowenstein, P.R.; Castro, M.G.; et al. Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine 2010, 28, 3371–3378. [Google Scholar]
  86. Ong, H.T.; Hasegawa, K.; Dietz, A.B.; Russell, S.J.; Peng, K.W. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther. 2007, 14, 324–333. [Google Scholar]
  87. Komarova, S.; Kawakami, Y.; Stoff-Khalili, M.A.; Curiel, D.T.; Pereboeva, L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol. Cancer Ther. 2006, 5, 755–766. [Google Scholar]
  88. Power, A.T.; Wang, J.; Falls, T.J.; Paterson, J.M.; Parato, K.A.; Lichty, B.D.; Stojdl, D.F.; Forsyth, P.A.; Atkins, H.; Bell, J.C. Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol. Ther. 2007, 15, 123–130. [Google Scholar]
  89. Fujiwara, S.; Nawa, A.; Luo, C.; Kamakura, M.; Goshima, F.; Kondo, C.; Kiyono, T.; Kikkawa, F.; Nishiyama, Y. Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer. Cancer Gene Ther. 2011, 18, 77–86. [Google Scholar]
  90. Eto, Y.; Yoshioka, Y.; Mukai, Y.; Okada, N.; Nakagawa, S. Development of PEGylated adenovirus vector with targeting ligand. Int. J. Pharm. 2008, 354, 3–8. [Google Scholar]
  91. Greish, K.; Frandsen, J.; Scharff, S.; Gustafson, J.; Cappello, J.; Li, D.; O’Malley, B.W., Jr.; Ghandehari, H. Silk-elastinlike protein polymers improve the efficacy of adenovirus thymidine kinase enzyme prodrug therapy of head and neck tumors. J. Gene Med. 2010, 12, 572–579. [Google Scholar]
  92. Fisher, K.D.; Seymour, L.W. HPMA copolymers for masking and retargeting of therapeutic viruses. Adv. Drug Deliv. Rev. 2010, 62, 240–245. [Google Scholar]
  93. Ikeda, K.; Ichikawa, T.; Wakimoto, H.; Silver, J.S.; Deisboeck, T.S.; Finkelstein, D.; Harsh, G.R., 4th; Louis, D.N.; Bartus, R.T.; Hochberg, F.H.; et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. 1999, 5, 881–887. [Google Scholar]
  94. Wakimoto, H.; Ikeda, K.; Abe, T.; Ichikawa, T.; Hochberg, F.H.; Ezekowitz, R.A.; Pasternack, M.S.; Chiocca, E.A. The complement response against an oncolytic virus is species-specific in its activation pathways. Mol. Ther. 2002, 5, 275–282. [Google Scholar]
  95. Heise, C.C.; Williams, A.; Olesch, J.; Kirn, D.H. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects. Cancer Gene Ther. 1999, 6, 499–504. [Google Scholar]
  96. Netti, P.A.; Berk, D.A.; Swartz, M.A.; Grodzinsky, A.J.; Jain, R.K. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000, 60, 2497–2503. [Google Scholar]
  97. Altomonte, J.; Marozin, S.; Schmid, R.M.; Ebert, O. Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol. Ther. 2010, 18, 275–284. [Google Scholar]
  98. Hong, C.S.; Fellows, W.; Niranjan, A.; Alber, S.; Watkins, S.; Cohen, J.B.; Glorioso, J.C.; Grandi, P. Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. Gene Ther. 2010, 17, 1200–1205. [Google Scholar]
  99. McKee, T.D.; Grandi, P.; Mok, W.; Alexandrakis, G.; Insin, N.; Zimmer, J.P.; Bawendi, M.G.; Boucher, Y.; Breakefield, X.O.; Jain, R.K. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res. 2006, 66, 2509–2513. [Google Scholar]
  100. Vile, R.; Ando, D.; Kirn, D. The oncolytic virotherapy treatment platform for cancer: Unique biological and biosafety points to consider. Cancer Gene Ther. 2002, 9, 1062–1067. [Google Scholar]
  101. Wisher, M. Biosafety and product release testing issues relevant to replication-competent oncolytic viruses. Cancer Gene Ther. 2002, 9, 1056–1061. [Google Scholar]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top